Extract notice to the Minister

Ilumya (psoriasis plaques)

Common name / Subject : tildrakizumab
Name of the manufacturer : Sun Pharma
Form : Sol. Inj. S. C. (ser)
Dosage : 100 mg/ml (1 ml)

Indication : Traitement du psoriasis en plaques

INESSS' Recommendation
Refus d'inscription

Minister's decisions
Ne pas inscrire aux listes des médicaments (2021-09-29)

Evaluation published on September 01, 2021

Download Advice to minister about Ilumya (psoriasis plaques)

Extrait de l'avis au ministre sur Ilumya 284 KiO

Subscribe to our newsletter now

Subscription